
    
      Patients with COVID-19 who are admitted with respiratory distress will be considered for
      enrollment on this study. Patients will be screened and then if they meet eligibility
      criteria will be enrolled. Abatacept will be administered on Day 1 at a dose of 10 mg/kg.
      Patients will then be followed closely through 90 days post-treatment.
    
  